Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis | Eli Lilly and Company The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Menu
Menu
Close
Close
Stock Info
Expand mega menu
Expand submenu
Left icon for back button
Back
Stock Info
Stock Quote & Chart
Historic Price Lookup